The whole world is working together to make a coronavirus vaccine. The United States is at the forefront of this. The world may get good news about this at the beginning of next year. But with the election looming, US President Donald Trump wants to get a vaccine before the election. His administration is even trying to speed up the vaccine approval process to cover up its failure to deal with corona, which has worried scientists.
The world may not have to wait too long to reap the benefits of a special initiative costing hundreds of billions of dollars and involving countless scientists and volunteers. Experts hope to get FDA approval bypassing the final stage of multiple possible vaccine tests early next year. But at the same time, the fear has been expressed that there is nothing wrong with rushing.
The New York Daily News reports that as the US election draws to a close, the administration’s pressure on vaccines is growing. The current administration wants to take credit for bringing a vaccine to the market earlier. The goal is to stay in an advantageous position in the upcoming elections. In this situation, a team of scientists has expressed concern.
A group of about 400 scientists and public health officials issued a joint statement on Wednesday (August 5th). They called on the FDA to follow a politically neutral and transparent approach to vaccine approval.
John P. Moore, a virologist at Well Colonel Medicine, who signed the letter, told the New York Daily: “The thing that worries many of us right now is the politicization of the (vaccine approval) system. The possibility of showing a surprise in October has been created.
But vaccine approval should be done properly. If this approval procedure were similar to hydroxychloroquine, how many more would be interested in getting this vaccine? If the vaccine is not credible to Americans, people will not accept it that way. And if that’s the case, it won’t work. “
But in the meantime, such fears have arisen. A recent Gallup poll found that one in three people in the United States say they are not interested in receiving an FDA-approved vaccine, even if it is given for free. The extent of the danger can be understood in the words of Anthony Fawcett. He said last month that if the potential vaccine was 80-75 percent effective, and if a quarter of people did not receive it, it would not work.
However, experts including John P. Moore still have full confidence in this regard. Anthony Fawcett. A member of the White House Coronavirus Task Force and a top infectious disease specialist in the United States still says it will have to wait until next year to get an effective vaccine.
“Hopefully, we have a number of options, all of which are good,” said Peter Pitts, a former FDA associate commissioner and current president of the Center for Medicine in the Public Interest. We have at least five possible vaccines in our hands, which are currently being tested in the third phase. The list includes vaccines made at Oxford University, Pfizer and Modern. However, these are not likely to arrive before February-March next year.
At the top of the list of possible vaccines is the vaccine made by the Novavax company. Last Tuesday, the company released information about this, which many experts think is promising. Moore is ahead of the others, especially in terms of antibody response. In Moore’s words, “I’m going to take the Novavax vaccine to make antibodies.”
However, Florian Kramer, a virologist at Mount Sinai Hospital, gives a slightly different opinion. He would rather use the vaccine made by AstraZeneca or Oxford as the original and the Novavax vaccine as the ‘antibody booster’. But the whole thing depends on the test. The FDA has a big responsibility in this regard. In this case, any kind of haste can cause great damage.
According to Kramer, having a lot of options on hand is definitely a big deal. But it is important to remember that this vaccine must be safe. Otherwise, it will be difficult to prevent any side effects. Once approved, the vaccine will reach at least 300 million people. As a result, utmost care must be taken in this case.
“Everything is being monitored,” Erin Silk, a spokeswoman for the New York Department of Health, told the New York Daily News about the scientists’ concerns and the overall situation. Keeping in touch with the federal administration. They say the use of the vaccine will be limited in the beginning.